Medicines for Europe https://validator.w3.org/feed/docs/rss2.html Recommendations to National Authorities on the Use of External Reference Pricing (ERP) Medicines for Ireland and Medicines for Europe welcome Irish Court referral of EU Water Directive to CJEU The off patent medicines industry is a strategic partner for Europe MEMO on a competitiveness strategy for the European healthcare sector Twenty years of the Legal Affairs Conference: Driving Europe’s competitiveness and timely access to medicines Review of the SPC Manufacturing Waiver: a 2026 Industry Report Critical Medicines Act: a step forward for secure medicines supply 32<sup>nd</sup> Annual Conference UWWTD: European Parliament stands with patients and security of medicine supplies 20<sup>th</sup> Legal Affairs Conference Key BIOS facts and Figures – 2026 The Biosimilar Advantage: Powering patient access and industrial resilience Biosimilars in the EU: Approval Overview and Therapeutic Areas Leading manufacturers appeal in proceedings against discriminatory wastewater fees on medicine before European Court of Justice EU policies must not push essential medicines off market: new Medicines for Europe president Biosimilar Medicines Conference Gemme is transforming and becoming ALMA – Alliance des Médicaments Abordables Key topics – REGULATORY AND LEGAL FRAMEWORK Biotech Act – Factsheet on European Biosimilar Medicines Sector: Delivering Impact Beyond Health – Economic, Scientific & Strategic Contribution Biotech Act – Factsheet on Optimising Intellectual Property (IP) Framework and Trade Partnerships ALMA (Alliance des Médicaments Abordables) DEMO Pharmaceuticals S.A. Factsheet on the Public procurement Directive Assessing the Cost Burden of UWWTD Extended Producer Responsibility on Pharmaceuticals: Implications for the accessibility, availability and affordability of medicines Policy recommendations on uptake of biosimilar medicines in the retail market Factsheet series on the Biotech Act Biotech Act – Factsheet on Developing Confidence in Biotech, Attractiveness, Talent and Skills Biotech Act – Factsheet on Reforming Regulations, Market Entry and Competition for Biosimilar medicines Biotech Act – Factsheet on Investing in Biotech R&D and Manufacturing Platforms Biotech Act – Factsheet on the Proposed 12-month Extension of the Supplementary Patent Protection (SPC) medac pharma production a.s Parliament makes the Critical Medicines Act meaningful but significant risks to future access persist ProGenerika (DE) Call to ‘Stop the Clock’ on UWWTD – Urgent reassessment needed to protect competitiveness and supply Product-level Life Cycle Assessments in the Off-Patent Sector Aurobindo Pharma 24<sup>th</sup> Regulatory Affairs Conference Open Letter on Critical Medicines Act trilogues negotations – The CMA must deliver on EU health security Open letter on the Critical Medicines Act trilogues negotiations – The CMA must deliver on EU health security Open letter on the urgent need to pause the UWWTD serious risk of causing tsunami of medicine shortages Position paper on the Revision of EU Rules on Public Procurement New EU Pharma Legislation to safeguard patient access and boost off-patent medicines efficiency ‘Access Is A Right, Not A Privilege’ – Medicines For Europe’s Saltofte Sets Out Priorities Overview of the pilots in Europe testing the use of the electronic product information (ePI) for medicines Samsung Bioepis Position paper on the Issue of Abuses of Divisional Patent Applications Press statement on UWWTD Court Decision Technical note on the Joint Research Centre report “Updated estimation of the costs of quaternary wastewater treatment in the EU” Pharos Medicines for Europe